Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-01-26 08:52 am Unchanged | 2022-12-31 | 13G | Coherus Oncology, Inc. CHRS | BlackRock Inc. BLK | 14,078,901 18.100% | 0 (Unchanged) | Filing History |
| 2023-01-20 09:43 am Purchase | 2022-12-31 | 13G | Coherus Oncology, Inc. CHRS | BlackRock Inc. BLK | 14,078,901 18.100% | 2,160,046 (+18.12%) | Filing History |
| 2023-01-18 1:30 pm Sale | 2022-12-30 | 13G | Coherus Oncology, Inc. CHRS | JPMORGAN CHASE & CO JPM | 5,663,770 7.200% | -691,417 (-10.88%) | Filing History |
| 2022-02-14 6:33 pm Purchase | 2021-12-31 | 13G | Coherus Oncology, Inc. CHRS | Perceptive Advisors LLC | 5,407,798 7.000% | 735,962 (+15.75%) | Filing History |
| 2022-02-14 2:45 pm Purchase | 2022-02-14 | 13G | Coherus Oncology, Inc. CHRS | AllianceBernstein L.P. | 5,668,528 7.400% | 1,012,629 (+21.75%) | Filing History |
| 2022-02-09 3:43 pm Purchase | 2021-12-31 | 13G | Coherus Oncology, Inc. CHRS | The Vanguard Group | 4,547,529 5.920% | 418,594 (+10.14%) | Filing History |
| 2022-02-09 12:40 pm Sale | 2021-12-31 | 13G | Coherus Oncology, Inc. CHRS | STATE STREET CORP STT | 3,821,120 4.980% | -797,930 (-17.27%) | Filing History |
| 2022-01-27 5:14 pm Unchanged | 2021-12-31 | 13G | Coherus Oncology, Inc. CHRS | BlackRock Inc. BLK | 11,918,855 15.500% | 0 (Unchanged) | Filing History |
| 2022-01-26 09:16 am Purchase | 2021-12-31 | 13G | Coherus Oncology, Inc. CHRS | BlackRock Inc. BLK | 11,918,855 15.500% | 1,390,505 (+13.21%) | Filing History |
| 2022-01-07 3:41 pm Purchase | 2021-12-31 | 13G | Coherus Oncology, Inc. CHRS | JPMORGAN CHASE & CO JPM | 6,355,187 8.200% | 1,392,505 (+28.06%) | Filing History |
| 2021-02-16 3:36 pm Purchase | 2020-12-31 | 13G | Coherus Oncology, Inc. CHRS | Perceptive Advisors LLC | 4,671,836 6.500% | 1,085,351 (+30.26%) | Filing History |
| 2021-02-10 10:46 am Purchase | 2020-12-31 | 13G | Coherus Oncology, Inc. CHRS | The Vanguard Group | 4,128,935 5.730% | 4,128,935 (New Position) | Filing History |
| 2021-02-08 08:30 am Purchase | 2020-12-31 | 13G | Coherus Oncology, Inc. CHRS | STATE STREET CORP STT | 4,619,050 6.410% | 4,619,050 (New Position) | Filing History |
| 2021-02-05 6:23 pm Purchase | 2021-02-15 | 13G | Coherus Oncology, Inc. CHRS | AllianceBernstein L.P. | 4,655,899 6.500% | 4,655,899 (New Position) | Filing History |
| 2021-01-26 2:22 pm Purchase | 2020-12-31 | 13G | Coherus Oncology, Inc. CHRS | BlackRock Inc. BLK | 10,528,350 14.600% | 369,351 (+3.64%) | Filing History |